Clinical Scorecard: FDA Approves Lilly’s Foundayo Oral GLP-1 Pill
At a Glance
| Category | Detail |
|---|---|
| Condition | Obesity and overweight with weight-related medical conditions |
| Key Mechanisms | Oral glucagon-like peptide-1 (GLP-1) receptor agonist promoting weight loss and cardiometabolic risk reduction |
| Target Population | Adults with obesity or overweight, including those with type 2 diabetes |
| Care Setting | Outpatient management with prescription access via LillyDirect, retail pharmacies, and telehealth |
Key Highlights
- Orforglipron (Foundayo) is a once-daily oral GLP-1 receptor agonist approved for chronic weight management.
- Phase 3 ATTAIN trials showed significant weight loss (up to 12.4% mean reduction) and improvements in cardiometabolic markers.
- Safety warnings include risk of thyroid tumors; contraindicated in patients with medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2.
Guideline-Based Recommendations
Diagnosis
- Identify adults with obesity or overweight and weight-related comorbidities eligible for chronic weight management.
Management
- Administer orforglipron once daily alongside reduced-calorie diet and increased physical activity.
- Avoid use in patients with personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2.
Monitoring & Follow-up
- Monitor for adverse events including gastrointestinal symptoms (nausea, diarrhea, constipation, vomiting).
- Surveillance for thyroid-related adverse effects due to potential tumor risk.
Risks
- Potential risk of thyroid tumors including thyroid cancer.
- Common adverse events: nausea, diarrhea, constipation, vomiting.
Patient & Prescribing Data
Adults with obesity or overweight, with or without type 2 diabetes, requiring chronic weight management
Significant weight loss demonstrated in clinical trials; available via LillyDirect and retail with variable copay assistance programs.
Clinical Best Practices
- Combine orforglipron therapy with lifestyle interventions including diet and exercise for optimal weight loss.
- Screen patients for thyroid cancer risk factors before initiating therapy.
- Educate patients on potential gastrointestinal side effects and monitor tolerability.
- Utilize savings programs to improve patient access and adherence.
Related Resources & Content
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
